{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:15:48Z","timestamp":1791821748953,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jbiotec.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T21:20:16Z","timestamp":1676841616000},"page":"62-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Investigation into the use of gamma irradiated Cytodex-1 microcarriers to produce a human cytomegalovirus (HCMV) vaccine candidate in epithelial cells"],"prefix":"10.1016","volume":"365","author":[{"suffix":"III","given":"Daniel","family":"Spatafore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Warakomski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sianny","family":"Christanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jbiotec.2023.02.005_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/586363","article-title":"Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2-litre stirred tank bioreactor","volume":"2010","author":"Arifin","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121015","article-title":"Risk analysis of leachables in cell and gene therapy using a CAR-T model process","volume":"607","author":"Budde","year":"2021","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib4","unstructured":"CDC. Cytomegalovirus (CMV) and Congenital CMV Infection. 18Aug2020 25Jan2022]; Available from: \u3008https:\/\/www.cdc.gov\/cmv\/index.html\u3009."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib5","unstructured":"Cytodex 1 Gamma Validation Guide. July 2021, Cytiva."},{"issue":"2","key":"10.1016\/j.jbiotec.2023.02.005_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/jcp.54.2.84","article-title":"Investigation of CMV disease in immunocompromised patients","volume":"54","author":"Emery","year":"2001","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib7","unstructured":"FDA. Cytomegalovirus in transplantation: developing drugs to treat or prevent disease. 07May2020; Available from: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cytomegalovirus-transplantation-developing-drugs-treat-or-prevent-disease\u3009."},{"issue":"6","key":"10.1016\/j.jbiotec.2023.02.005_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1208\/s12248-020-00521-5","article-title":"Monoclonal antibody reagent stability and expiry recommendation combining experimental data with mathematical modeling","volume":"22","author":"Fink","year":"2020","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.jbiotec.2023.02.005_bib9","first-page":"1","article-title":"Human cytomegalovirus (HCMV) infection\/re-infection: development of a protective HCMV vaccine","volume":"42","author":"Gerna","year":"2019","journal-title":"N. Microbiol"},{"issue":"18","key":"10.1016\/j.jbiotec.2023.02.005_bib10","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.jbiotec.2023.02.005_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5731\/pdajpst.2013.00905","article-title":"Identification of a leachable compound detrimental to cell growth in single-use bioprocess containers","volume":"67","author":"Hammond","year":"2013","journal-title":"PDA J. Pharm. Sci. Technol."},{"issue":"Suppl 1","key":"10.1016\/j.jbiotec.2023.02.005_bib12","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/infdis\/jiz389","article-title":"The development of therapeutics for the treatment and prevention of CMV disease in the transplant population: a regulatory perspective","volume":"221","author":"Hodowanec","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.csbj.2016.06.007","article-title":"A single-use strategy to enable manufacturing of affordable biologics","volume":"14","author":"Jacquemart","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"8","key":"10.1016\/j.jbiotec.2023.02.005_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1517\/14656566.2.8.1247","article-title":"Cytomegalovirus treatment options in immunocompromised patients","volume":"2","author":"Khare","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107608","article-title":"Vero cell upstream bioprocess development for the production of viral vectors and vaccines","volume":"44","author":"Kiesslich","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103810","article-title":"Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 \/ TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study","volume":"75","author":"Launay","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jbiotec.2023.02.005_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202000020","article-title":"Evaluation of the single-use fixed-bed bioreactors in scalable virus production","volume":"16","author":"Lesch","year":"2021","journal-title":"Biotechnol. J."},{"issue":"51","key":"10.1016\/j.jbiotec.2023.02.005_bib18","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1016\/j.vaccine.2021.10.075","article-title":"Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jbiotec.2023.02.005_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41541-021-00342-3","article-title":"A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial","volume":"6","author":"Li","year":"2021","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1921","article-title":"Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy","volume":"27","author":"Lilleri","year":"2017","journal-title":"Rev. Med. Virol."},{"issue":"35","key":"10.1016\/j.jbiotec.2023.02.005_bib21","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1016\/j.vaccine.2015.04.050","article-title":"Increasing Vero viable cell densities for yellow fever virus production in stirred-tank bioreactors using serum-free medium","volume":"33","author":"Mattos","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.jbiotec.2023.02.005_bib22","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The status of vaccine development against the human cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jbiotec.2023.02.005_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/rmv.315","article-title":"A review of genetic differences between limited and extensively passaged human cytomegalovirus strains","volume":"11","author":"Prichard","year":"2001","journal-title":"Rev. Med Virol."},{"issue":"5","key":"10.1016\/j.jbiotec.2023.02.005_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.jbiotec.2023.02.005_bib25","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jbiotec.2023.02.005_bib26","unstructured":"Regulatory Support File Cytodex 1. March 2018, GE Healthcare."},{"issue":"10165","key":"10.1016\/j.jbiotec.2023.02.005_bib27","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jbiotec.2023.02.005_bib28","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1038\/s41598-021-86571-x","article-title":"Adsorption of bacteriophages on polypropylene labware affects the reproducibility of phage research","volume":"11","author":"Richter","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jbiotec.2023.02.005_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.spid.2004.09.011","article-title":"Congenital cytomegalovirus infection: outcome and diagnosis","volume":"16","author":"Ross","year":"2005","journal-title":"Semin. Pediatr. Infect. Dis."},{"issue":"19","key":"10.1016\/j.jbiotec.2023.02.005_bib30","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.vaccine.2007.01.086","article-title":"A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions","volume":"25","author":"Rourou","year":"2007","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.jbiotec.2023.02.005_bib31","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1016\/j.vaccine.2021.06.033","article-title":"Characterization of gH\/gL\/pUL128-131 pentameric complex, gH\/gL\/gO trimeric complex, gB and gM\/gN glycoproteins in a human cytomegalovirus using automated capillary western blots","volume":"39","author":"Rustandi","year":"2021","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.jbiotec.2023.02.005_bib32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.vaccine.2013.11.044","article-title":"Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor","volume":"32","author":"Tapia","year":"2014","journal-title":"Vaccine"},{"issue":"362","key":"10.1016\/j.jbiotec.2023.02.005_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"16","key":"10.1016\/j.jbiotec.2023.02.005_bib34","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.1128\/JVI.79.16.10330-10338.2005","article-title":"Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism","volume":"79","author":"Wang","year":"2005","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jbiotec.2023.02.005_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13568-019-0794-5","article-title":"Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors","volume":"9","author":"Yang","year":"2019","journal-title":"AMB Express"}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016816562300038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016816562300038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:01:16Z","timestamp":1759150876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016816562300038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":35,"alternative-id":["S016816562300038X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2023.02.005","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation into the use of gamma irradiated Cytodex-1 microcarriers to produce a human cytomegalovirus (HCMV) vaccine candidate in epithelial cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA.  Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}